arrow_back Back to App

Increased Funding for New Drug and Therapy Development

This bill increases funding for programs that accelerate the creation and market introduction of new drugs and therapies. This means citizens can anticipate faster access to innovative treatments for various diseases. More resources support collaboration between scientists and companies, speeding up medical research.
Key points
Increased funding for research programs from $6 million to $10 million annually for fiscal years 2023-2027.
Support for faster development and availability of new drugs and therapies for patients.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7658
Sponsor: Rep. O'Halleran, Tom [D-AZ-1]
Process start date: 2022-05-03
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7658.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-05-03.

What are the main provisions?

Key points include:

  • Increased funding for research programs from $6 million to $10 million annually for fiscal years 2023-2027.
  • Support for faster development and availability of new drugs and therapies for patients.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. O'Halleran, Tom [D-AZ-1].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health